← Back to Search

Platelet Rich Plasma Therapy

Autologous Conditioned Plasma (ACP) for Patients With Plantar Fasciitis

N/A
Waitlist Available
Research Sponsored by University of Western Ontario, Canada
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 weeks, 3, 6 and 12 months
Awards & highlights
All Individual Drugs Already Approved
Approved for 10 Other Conditions
No Placebo-Only Group

Summary

Plantar fasciitis presents clinically as pain in the inner heal, which is the result of degeneration of the plantar fascia, an arch supporting ligament of the foot. It manifests predominantly in those subjected to sustained weight bearing or repetitive pounding activities. Plantar fasciitis is the most common cause of inferior foot pain. Although most cases resolving within 6 months, traditional treatment regiments such as orthotics and physiotherapy are occasionally unsuccessful in treating this limitation leading to chronic symptoms (Neufeld \& Cerrato, 2008; Rompe, 2009; Roxas, 2005). Platelets are central players in clotting, inflammation and the wound healing response. Research has shown the potential of platelet rich plasma to accelerate wound healing in a variety of conditions including maxillo-fascial and plastic surgery, chronic wound healing and orthopaedics. Autologous Conditioned Plasma (ACP) is a novel treatment that may accelerate the healing of injured tissue. Treatment with ACP involves taking a blood sample from the patient, isolating the platelets and injecting them back into that patient at the injury site

Eligible Conditions
  • Plantar Fasciitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 weeks, 3, 6 and 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks, 3, 6 and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
American Orthopaedic Foot and Ankle Midfoot Scale (AOFAS)

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: ACP treatmentActive Control1 Intervention
Group II: Corticosteroid treatmentActive Control1 Intervention

Find a Location

Who is running the clinical trial?

University of Western Ontario, CanadaLead Sponsor
166 Previous Clinical Trials
319,218 Total Patients Enrolled
Arthrex, Inc.Industry Sponsor
46 Previous Clinical Trials
29,832 Total Patients Enrolled
Dianne Bryant, PhDStudy DirectorThe University of Western Ontario
3 Previous Clinical Trials
142 Total Patients Enrolled
~9 spots leftby Jan 2026